Developer docs
API playgroundTry for free, no card

Search company profiles

Magenta Medical

Full company profile

uuid0000o3j

Namestring
Magenta Medical
Legal namestring
Magenta Medical Ltd.
Websiteurl
magentamed.com
Company typeenum
Private
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersKadima, Israel
HQ citystring
Kadima
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
percutaneous heart pump, mechanical circulatory support, left ventricular assist device, interventional cardiology devices, cardiogenic shock therapy
Industry2 codes
1Mechanical Circulatory Support (VAD, IABP, ECMO)
CodeHLAHAFAGPrimaryYes
2Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
CodeHLAHAFALPrimaryNo
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Assist Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Elevate™ System Medical Device Sales
TypeHardware Sales
Description

Magenta Medical generates revenue through the sale of its Elevate™ percutaneous left ventricular assist device (pLVAD). The company is currently in pre-commercial stage, seeking FDA approval before commercialization in the U.S. market. The device is intended for temporary mechanical circulatory support during high-risk PCI procedures and for cardiogenic shock patients.

magentamed.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Magenta Medical develops the Elevate™ percutaneous Left Ventricular Assist Device (pLVAD), a self-expanding miniaturized catheter-mounted axial-flow pump designed to provide temporary mechanical circulatory support for the left ventricle during high-risk percutaneous coronary interventions (HR-PCI) and for patients admitted with cardiogenic shock. The device is delivered through a 10 Fr femoral introducer sheath and expands from 9 Fr to 30 Fr inside the ventricle, delivering over 5.4 L/min of mean flow. The company is in pre-commercial stage, pursuing FDA approval before commercialization in the U.S.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Magenta Medical is a medical device company that has developed a single core product—the Elevate™ System—which is a percutaneous Left Ventricular Assist Device (pLVAD). The Elevate™ System is a self-expanding miniature heart pump designed for temporary mechanical circulatory support during high-risk coronary interventions and for cardiogenic shock patients. The company was previously developing a device under the KADIMA project name, which has since been unified under the Elevate™ System brand. The product is not yet commercially available in any jurisdiction and is currently pursuing FDA approval.

Product and service1 record
1Elevate™ System (Percutaneous Left Ventricular Assist Device)
CategoryPercutaneous Ventricular Assist Devices (pVADs)
Description

A self-expanding percutaneous Left Ventricular Assist Device (pLVAD) delivered through a 10 Fr femoral introducer sheath that expands from 9 Fr to 30 Fr inside the left ventricle and delivers over 5.4 L/min of mean flow (peak exceeding 8 L/min). Intended for temporary mechanical circulatory support during high-risk percutaneous coronary interventions (HR-PCI) and for treatment of patients admitted with cardiogenic shock. Targeted at interventional cardiologists and cardiac care centers in U.S. hospitals upon FDA approval.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Medtronic (Ventor Technologies)
Strategic tierMinorTypeOthersAnnounced on2012-01-01
Description

Magenta Medical's co-founders (Yosi Tuval and Ehud Schwammenthal) previously founded Ventor Technologies, which was acquired by Medtronic in 2009. The founders bring prior medtech development experience from Medtronic Ventor Technologies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Abiomed (Johnson & Johnson MedTech)
TypeDirect peer
Description

Abiomed's Impella is the dominant percutaneous LVAD platform and the most direct competitor to Magenta's Elevate, addressing the same HR-PCI and cardiogenic shock indications. Abiomed is also a Magenta investor from the 2017 Series B round, making the relationship both competitive and financial.

2LivaNova
TypeDirect peer
Description

LivaNova's TandemLife / ProtekDuo and LifeSPARC systems offer temporary mechanical circulatory support platforms overlapping with Elevate's cardiogenic shock and ECMO-adjacent use cases. Both target interventional cardiology and cardiac surgery centers for short-term ventricular support.

3Medtronic
TypeBroad incumbent
Description

Medtronic is a broad cardiovascular incumbent with mechanical circulatory support (HVAD historical, HeartWare legacy) and acquired Magenta co-founders' prior company Ventor Technologies. Competes indirectly via broader cardiac surgery and structural heart portfolios.

4Edwards Lifesciences
TypeBroad incumbent
Description

Edwards Lifesciences is a structural heart and critical care leader whose heart failure therapies portfolio overlaps with Magenta's downstream patient population. COO David Zollinger's prior leadership at Edwards signals comparable commercial DNA but Edwards focuses on surgical/structural heart rather than pVADs.

5Boston Scientific
TypeBroad incumbent
Description

Boston Scientific has a broad interventional cardiology portfolio (including drug-eluting stents, IVL, and acquired cardiac assist assets). It is a broader incumbent rather than a direct pVAD competitor but serves the same HR-PCI cath lab customer base.

6Teleflex
TypeBroad incumbent
Description

Teleflex markets intra-aortic balloon pumps (IABP) like the Arrow AC3 Optimus, an older but still-used mechanical circulatory support modality that competes at the lower-acuity end of the HR-PCI and cardiogenic shock segments Magenta targets.

7Cardiobridge (Fresenius Medical Care / Xenios)
TypeEmerging player
Description

Cardiobridge developed the Reitan catheter-mounted pump — a conceptually similar percutaneous LVAD — before being acquired by Xenios (now part of Fresenius). It is a European pVAD competitor targeting comparable high-risk PCI indications.

8Procyrion
TypeEmerging player
Description

Procyrion is developing the Aortix percutaneous mechanical circulatory support pump, a catheter-deployed pump for chronic heart failure and cardiogenic shock. It targets overlapping patient populations but with a different deployment site (descending aorta vs. left ventricle).

9Windmill Cardiovascular Systems
TypeEmerging player
Description

Windmill is developing the TEMP (Temporary Endovascular Myocardial Support) system, a catheter-deployed pump targeting temporary mechanical circulatory support. It is a smaller emerging competitor pursuing a similar percutaneous support thesis to Magenta.

10Penumbra
TypeOthers
Description

Penumbra is a catheter-based intervention company primarily known for thrombectomy, but is expanding into cardiovascular and structural heart adjacencies. While not a pVAD competitor, it shares the minimally-invasive catheter-based interventional cardiology commercial channel.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Magenta Medical

Cardiac Assist Devicesmagentamed.com

Magenta Medical firmographics

Firmographics
Name
Magenta Medical
Legal name
Magenta Medical Ltd.
Website
https://magentamed.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Magenta Medical industry classification

Industry
Product category
Cardiac Assist Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)
akta.pro secondary industry
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

Keywords

  • Percutaneous heart pump
  • Mechanical circulatory support
  • Left ventricular assist device
  • Interventional cardiology devices
  • Cardiogenic shock therapy

Where Magenta Medical is headquartered

Location

Headquarters

HQ city
Kadima
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Magenta Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Elevate™ System Medical Device Sales: Magenta Medical generates revenue through the sale of its Elevate™ percutaneous left ventricular assist device (pLVAD). The company is currently in pre-commercial stage, seeking FDA approval before commercialization in the U.S. market. The device is intended for temporary mechanical circulatory support during high-risk PCI procedures and for cardiogenic shock patients.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Magenta Medical product offering

Product offering

Core offering

Magenta Medical develops the Elevate™ percutaneous Left Ventricular Assist Device (pLVAD), a self-expanding miniaturized catheter-mounted axial-flow pump designed to provide temporary mechanical circulatory support for the left ventricle during high-risk percutaneous coronary interventions (HR-PCI) and for patients admitted with cardiogenic shock. The device is delivered through a 10 Fr femoral introducer sheath and expands from 9 Fr to 30 Fr inside the ventricle, delivering over 5.4 L/min of mean flow. The company is in pre-commercial stage, pursuing FDA approval before commercialization in the U.S.

Product overview

Magenta Medical is a medical device company that has developed a single core product—the Elevate™ System—which is a percutaneous Left Ventricular Assist Device (pLVAD). The Elevate™ System is a self-expanding miniature heart pump designed for temporary mechanical circulatory support during high-risk coronary interventions and for cardiogenic shock patients. The company was previously developing a device under the KADIMA project name, which has since been unified under the Elevate™ System brand. The product is not yet commercially available in any jurisdiction and is currently pursuing FDA approval.

Differentiator

Problem solved

Functional benefit

Products and services

  • Elevate™ System (Percutaneous Left Ventricular Assist Device) A self-expanding percutaneous Left Ventricular Assist Device (pLVAD) delivered through a 10 Fr femoral introducer sheath that expands from 9 Fr to 30 Fr inside the left ventricle and delivers over 5.4 L/min of mean flow (peak exceeding 8 L/min). Intended for temporary mechanical circulatory support during high-risk percutaneous coronary interventions (HR-PCI) and for treatment of patients admitted with cardiogenic shock. Targeted at interventional cardiologists and cardiac care centers in U.S. hospitals upon FDA approval.

Companies that use Magenta Medical

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Magenta Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Magenta Medical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Medtronic (Ventor Technologies)minorOthers · 1 January 2012Magenta Medical's co-founders (Yosi Tuval and Ehud Schwammenthal) previously founded Ventor Technologies, which was acquired by Medtronic in 2009. The founders bring prior medtech development experience from Medtronic Ventor Technologies.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Magenta Medical competitors and assessment

Company assessment

Direct peers

  • Abiomed (Johnson & Johnson MedTech): Abiomed's Impella is the dominant percutaneous LVAD platform and the most direct competitor to Magenta's Elevate, addressing the same HR-PCI and cardiogenic shock indications. Abiomed is also a Magenta investor from the 2017 Series B round, making the relationship both competitive and financial.
  • LivaNova: LivaNova's TandemLife / ProtekDuo and LifeSPARC systems offer temporary mechanical circulatory support platforms overlapping with Elevate's cardiogenic shock and ECMO-adjacent use cases. Both target interventional cardiology and cardiac surgery centers for short-term ventricular support.

Broad incumbents

  • Medtronic: Medtronic is a broad cardiovascular incumbent with mechanical circulatory support (HVAD historical, HeartWare legacy) and acquired Magenta co-founders' prior company Ventor Technologies. Competes indirectly via broader cardiac surgery and structural heart portfolios.
  • Edwards Lifesciences: Edwards Lifesciences is a structural heart and critical care leader whose heart failure therapies portfolio overlaps with Magenta's downstream patient population. COO David Zollinger's prior leadership at Edwards signals comparable commercial DNA but Edwards focuses on surgical/structural heart rather than pVADs.
  • Boston Scientific: Boston Scientific has a broad interventional cardiology portfolio (including drug-eluting stents, IVL, and acquired cardiac assist assets). It is a broader incumbent rather than a direct pVAD competitor but serves the same HR-PCI cath lab customer base.
  • Teleflex: Teleflex markets intra-aortic balloon pumps (IABP) like the Arrow AC3 Optimus, an older but still-used mechanical circulatory support modality that competes at the lower-acuity end of the HR-PCI and cardiogenic shock segments Magenta targets.

Emerging players

  • Cardiobridge (Fresenius Medical Care / Xenios): Cardiobridge developed the Reitan catheter-mounted pump — a conceptually similar percutaneous LVAD — before being acquired by Xenios (now part of Fresenius). It is a European pVAD competitor targeting comparable high-risk PCI indications.
  • Procyrion: Procyrion is developing the Aortix percutaneous mechanical circulatory support pump, a catheter-deployed pump for chronic heart failure and cardiogenic shock. It targets overlapping patient populations but with a different deployment site (descending aorta vs. left ventricle).
  • Windmill Cardiovascular Systems: Windmill is developing the TEMP (Temporary Endovascular Myocardial Support) system, a catheter-deployed pump targeting temporary mechanical circulatory support. It is a smaller emerging competitor pursuing a similar percutaneous support thesis to Magenta.

Others

  • Penumbra: Penumbra is a catheter-based intervention company primarily known for thrombectomy, but is expanding into cardiovascular and structural heart adjacencies. While not a pVAD competitor, it shares the minimally-invasive catheter-based interventional cardiology commercial channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Magenta Medical social profiles

Digital presence

Magenta Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Magenta Medical leadership team

Management profile

Number of profiles

Profiles4 records

Magenta Medical funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Magenta Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Magenta Medical

What does Magenta Medical do?

Magenta Medical develops the Elevate™ percutaneous Left Ventricular Assist Device (pLVAD), a self-expanding miniaturized catheter-mounted axial-flow pump designed to provide temporary mechanical circulatory support for the left ventricle during high-risk percutaneous coronary interventions (HR-PCI) and for patients admitted with cardiogenic shock. The device is delivered through a 10 Fr femoral introducer sheath and expands from 9 Fr to 30 Fr inside the ventricle, delivering over 5.4 L/min of mean flow. The company is in pre-commercial stage, pursuing FDA approval before commercialization in the U.S.

Is Magenta Medical a public or private company?

Magenta Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Magenta Medical founded?

Magenta Medical was founded in 2012. It employs 51 to 100 people.

Where is Magenta Medical based?

Magenta Medical is headquartered in Kadima, Israel, in the Middle East region.

How does Magenta Medical make money?

One revenue line is on record: elevate™ System Medical Device Sales.

Who are Magenta Medical's main competitors?

Direct peers on record are Abiomed (Johnson & Johnson MedTech) and LivaNova. Broad incumbents are Medtronic, Edwards Lifesciences, Boston Scientific and Teleflex. Emerging players are Cardiobridge (Fresenius Medical Care / Xenios), Procyrion and Windmill Cardiovascular Systems. Penumbra is listed as an others.

Does Magenta Medical have an API?

No public API is recorded for Magenta Medical.

What industry is Magenta Medical in?

Magenta Medical's product category is Cardiac Assist Devices. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device and Diagnostic industryMagenta Medical Looks to Secure Place in MCS MarketMagenta Medical raised $105 million to advance its Elevate pLVAD, which targets the mechanical circulatory support market. The device offers a smaller insertion size and higher blood flow than Johnson & Johnson's Impella, with results from an early feasibility study for high-risk PCI patients presented at TCT 2023.Pulse 2.0Magenta Medical: Heart Pump Company Raises $105 MillionMagenta Medical closed a $105 million funding round led by Novo Holdings, with participation from Viking Global Investors, RA Capital Management, and existing investors. The funds will advance U.S. clinical programs for its Elevate heart pump, aiming for the first FDA approval in high-risk percutaneous coronary interventions. The company is preparing a pivotal U.S. study.FinSMEsMagenta Medical Closes $105M FinancingMagenta Medical raised $105M in funding led by Novo Holdings, with participation from Viking Global Investors, RA Capital Management, and existing investors. The company will use the funds to advance U.S. clinical programs and secure the first FDA approval for its Elevate™ System in high-risk percutaneous coronary interventions.CTechMagenta Medical nets $105M to secure FDA approval for world's smallest heart pumpMagenta Medical has closed a $105 million financing round led by Novo Holdings to advance its U.S. clinical programs and secure FDA approval for the Elevate heart pump. The funding brings the company's total capital raised to $183 million as it targets first-time approval for use in patients undergoing high-risk percutaneous coronary interventions. This capital will support the development of the world's smallest mechanical circulatory support device.MassDeviceMagenta Medical raises $105M for world’s smallest heart pumpMagenta Medical closed a $105 million financing round led by Novo Holdings to advance its Elevate heart pump technology. The company plans to use the funds to launch a pivotal study in the U.S. and seek FDA approval for treating high-risk percutaneous coronary interventions and cardiogenic shock. This investment builds on previous funding and supports Magenta's goal of disrupting the mechanical circulatory support market with its miniaturized device.WsjExclusive | Heart-Pump Developer Magenta Medical Raises $105 MillionMagenta Medical has raised $105 million in venture capital funding to develop its heart pump technology and compete in the cardiac device market. The company is positioning itself against major players like Johnson & Johnson, which acquired Abiomed for $16.6 billion in 2022.PR NewswireMagenta Medical Reports Positive Results for US Early Feasibility Study of Elevate™ Heart Pump in Providing Temporary Mechanical Circulatory Support During High-Risk PCI ProceduresThe US Early Feasibility Study of Magenta Medical's Elevate™ System demonstrated successful outcomes in providing temporary mechanical circulatory support during high-risk percutaneous coronary intervention (HR-PCI) procedures. All 15 patients treated in the study were discharged alive and well, without major complications, highlighting the effectiveness of the device.PR NewswireResults from Magenta Medical's US Early Feasibility Study of the World's Smallest and Most Powerful Heart Pump to be Highlighted at TCT 2023Magenta Medical announced that results from its US Early Feasibility Study of the Elevate™ percutaneous Left Ventricular Assist Device will be presented at the TCT 2023 conference in San Francisco. The study, conducted at Mount Sinai Hospital and other centers, evaluated the safety and feasibility of the device for high-risk percutaneous coronary interventions in fifteen patients.PR NewswireResults from Magenta Medical's US Early Feasibility Study of the World's Smallest and Most Powerful Heart Pump to be Highlighted at TCT 2023Results from Magenta Medical's Early Feasibility Study of the Elevate™ System will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. The study involved fifteen patients and evaluated the device's safety and feasibility for high-risk percutaneous coronary interventions. The Elevate™ pLVAD, designed for temporary mechanical circulatory support, has received Breakthrough Device Designation from the FDA for specific indications.DAICMagenta Medical Completes Enrollment to Early Feasibility Study for World’s Smallest Heart PumpMagenta Medical announced the completion of enrollment for its FDA-approved Early Feasibility Study of the Elevate heart pump system, a device designed for high-risk percutaneous coronary interventions. The study enrolled 15 patients across three US hospitals to evaluate the safety and feasibility of the miniaturized pump for temporary mechanical circulatory support.